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In July 2009, the Center for Mental Health Research on AIDS at the National
Institute of Mental Health organized and supported the meeting “NeuroAIDS
in Africa.” This meeting was held in Cape Town, South Africa, and was
affiliated with the 5th IAS Conference on HIV Pathogenesis, Treatment and
Prevention. Presentations began with an overview of the epidemiology of HIV
in sub-Saharan Africa, the molecular epidemiology of HIV, HIV-associated
neurocognitive disorders (HANDs), and HAND treatment. These introductory
talks were followed by presentations on HAND research and clinical care in
Botswana, Cameroon, Ethiopia, The Gambia, Kenya, Malawi, Nigeria, Sene-
gal, South Africa, Uganda, and Zambia. Topics discussed included best
practices for assessing neurocognitive disorders, patterns of central nervous
system (CNS) involvement in the region, subtype-associated risk for HAND,
pediatric HIV assessments and neurodevelopment, HIV-associated CNS
opportunistic infections and immune reconstitution syndrome, the evolving
changes in treatment implementation, and various opportunities and strat-
egies for NeuroAIDS research and capacity building in the region. Journal of
NeuroVirology (2010) 16, 189–202.
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Introduction
In July 2009, the Center for Mental Health Research
on AIDS at the National Institute of Mental Health
organized and supported the meeting “NeuroAIDS in
Africa.” This meeting was held in Cape Town, South
Africa, and was affiliated with the 5th IAS Confer-
ence on HIV Pathogenesis, Treatment and Preven-
tion. The goals of the meeting included:
1. Reviewing findings of neurocognitive impairment
directlyattributable toHIVatdifferentAfricansites
2. Determining the impact of comorbid factors such
as coinfections (tuberculosis [TB], malaria, syph-
ilis, toxoplasmosis, cryptococcal meningitis, etc.),
psychiatric illness, or nutritional deficiencies on
neurocognitive function
3. Discussing relationships between neurocognitive
impairmentandHIVdiseasevariables (currentand
nadir CD4, viral load, biomarkers of HIV neuro-
pathogenesis, neuroimaging, and brain pathology)
4. Evaluating differences in HIV-1 subtype-
associated neuropathology
5. Evaluating the relationships between HIV-
associated neurocognitive impairment and abil-
ity to perform activities of daily living within
different African populations
In addition to these goals, conference participants
discussed the challenges to NeuroAIDS research in
Africa as related to infrastructure, access to neuro-
logical and neuropsychological expertise, regional
HIV genetic variability, host population genetics,
differences in comorbidities and coinfections, avail-
ability of appropriate normative/control data for neu-
ropsychological assessments, differences in language
and culture, and differences in methods used across
studies. Efforts were made at this meeting to further
establish a more standardized approach to neurocog-
nitive assessments across international studies, and
expand on best practices for areas of concern such as
developing appropriate normal data, identifying and
categorizing levels of comorbidities, training local
investigators, and assessing the relative impact of
neurocognitive impairment on everyday functioning,
in order to improve future NeuroAIDS research in
Africa and other resource-limited settings.
Overview of epidemiology and neurological
disease
Epidemiology of HIV/CNS disease in sub-Saharan
Africa
Dr. Hakim gave an overview of the epidemiology of
HIV and central nervous system (CNS) disease in
sub-Saharan Africa. According to the 2008 UNAIDS
Report on the Global AIDS Epidemic, approximately
22 million (67%) of the estimated 33 million adults
and children living with HIV globally, reside in sub-
Saharan Africa (WHO/UNAIDS, 2008). Of the esti-
mated 2.7 million adults and children newly infected
with HIV worldwide in 2007, 1.9 million new infec-
tions occurred in sub-Saharan Africa as well as
1.5 million of the estimated 2 million adult and child
deaths due to AIDS. Although sub-Saharan Africa is
certainly still in dire straits, the 2008 UNAIDS report
offered some signs of improvement. The 2008
UNAIDS Report on the Global AIDS Epidemic con-
firmed progress in the response to AIDS, stating that
governments are acting on their promises to scale up
diagnosis, prognosis, and care for HIV-infected indi-
viduals, that financing for HIV treatment in low-to-
middle-income countries has increased 6-fold and
that additional countries (Lesotha, Namibia, Repub-
lic of South Africa [RSA], and Swaziland, for exam-
ple) have had improvements in the epidemic (WHO/
UNAIDS, 2008). CNS opportunistic infections (OIs)
such as tuberculosis (meningitis, tuberculoma), cryp-
tococcal meningitis, toxoplasmosis, neurocyster-
cercosis, neurosyphilis, primary CNS lymphoma
(Epstein-Barr virus), progressive multifocal leuko-
encephalopathy (JC virus), cytomegalovirus, as well
as stroke remain the most commonly described HIV-
associated CNS diseases. Cognitive dysfunction such
as dementia and psychological perturbations un-
related to OIs above has been less commonly
described. Dr. Hakim acknowledged problems with
our understanding of HIV-associated CNS disease in
sub-Saharan Africa, largely due to limited data on
these conditions, in part due to the paucity of neurol-
ogists managing HIV-infected patients. In addition,
confidently confirming diagnoses is difficult due to
comorbid conditions, limited imaging facilities, and
limited diagnostic capabilities (microbiological,
immunological, virologic, serologic, histologic, etc.).
Molecular epidemiology of HIV in Africa
Dr. Sankalé presented a review of the molecular
epidemiology of HIV. HIV exhibits tremendous
genetic diversity, which has been attributed to the
lack of proofreading of reverse transcriptase, rapid
turnover of virions, constant recombination of
viruses, RNA polymerase II errors, and selective
immunologic pressures. The HIV-1 genome encodes
nine open reading frames: gag, pol, env, tat, rev, nef,
vpr, vif, and vpu. Major variations in these genes
allow for HIV to be classified at a number of levels,
beginning with distinctions between HIV-1 and
HIV-2. HIV-1 consists of several major groups that
include group M (Major), the source of the vast
majority of HIV infections worldwide, as well as
groups O (Outlier) and N (non-M, non-O). Within
group M, HIV can be further distinguished into
clades or subtypes, such as clades A–D, F–H, J, K,
circulating recombinant forms (CRFs) A/E and A/G,
many other circulating recombinant forms (which
now number over 40) (LANL, 2010) as well as unique
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recombinant forms. The distribution of HIV-1 sub-
types and recombinants varies by region of the world,
by country, and even within a country such as
Nigeria. Within Africa, CRF02_AG accounts for the
bulk of infections in West Africa, subtypes A and D
are common in East Africa, and subtype C predomi-
nates in Southern Africa as well as Northeastern areas
such as Ethiopia (Hemelaar et al, 2006). Differences
in disease progression and resistance profiles were
also discussed. A study of registered female sex work-
ers in Dakar, Senegal, determined that HIV-2 is less
infectious, has a much lower mother-to-child trans-
mission rate, and a much longer progression time to
AIDS than HIV-1. Studies investigating differences in
HIV-1 subtypes found that subtype A has a longer
AIDS-free survival than non-A (Kanki et al, 1999);
subtype D has a shorter time to death and AIDS than
subtype A, C, or recombinant forms (Vasan et al,
2006); and in subtype C, CCR5/non–syncytia-forming
viruses are almost always the dominant form even in
late stages of infection (Tscherning et al, 1998). HIV-2
and HIV-1 type O possess a primary resistance to
non-nucleoside reverse transcriptase inhibitors
(NNRTIs) (Descamps et al, 1997; Ren et al, 2002).
Naturally occurring minor mutations in the protease
sequences of many non-B subtypes such as subtype F
(Poveda et al, 2008) can also confer resistance. Few
naturally occurring polymorphisms at resistance
positions in reverse transcriptase in type M viruses
have been discovered.
There is a potential role for clade differences in
varying neuropathogenicity. How much of a role
clades play in the neuropathogenicity of HIV will be
difficult to determine because treatment availability
and practices vary from place to place and measures
of cognitive and functional performance are inher-
ently subject to some degree of cultural influence.
HIV-associated neurocognitive disorders
Dr. Grant gave a summary of HIV-associated neuro-
cognitive disorders (HANDs), which remain to be
common problems in HIV-infected patients despite
the success of combination antiretrovirals at improv-
ing overall health and prolonging survival. The
nosology of HAND, revised in 2007 (Antinori et al,
2007), now includes three classifications: asymptom-
atic neuropsychological impairment (abnormality in
two or more cognitive abilities), mild neurocognitive
disorder (cognitive impairment with mild functional
impairment), and HIV-associated dementia (marked
cognitive impairment with marked functional
impairment). Neuropsychological (NP) deficits in
measures of attention, learning, verbal, motor, mem-
ory, psychomotor, sensory, and abstraction are the
most common among patients with global NP
impairment. HAND prevalence rates still range
from 30% to 50% and the cognitive profile, or areas
of impairment, has not changed significantly. One
third of patients have magnetic resonance imaging
(MRI) evidence of white matter abnormality and
approximately 34% (perhaps up to 60%) have
detectable HIV RNA in the cerebrospinal fluid (CSF).
The possible mechanisms for neurotoxicity in
HIV-1 infection include direct damage to neurons
caused by shed viral proteins, but not infection of
neurons themselves, as well as indirect damage
caused by neurotoxic molecules released by activated
and/or infected astrocytes, macrophages, and micro-
glia. HIV infection preferentially causes damage to
the basal ganglia and white matter, but loss of
dendritic complexity and the degree and synaptoden-
dritic injury are also strongly associated with pro-
gressive neurocognitive impairment. Cofactors in
HIV-associated neurocognitive complications such
as drug abuse (e.g., methamphetamine), coinfections
(e.g., hepatitis C), aging, immune reconstitution syn-
drome, neurotoxic treatments, and other background
factors (e.g., head injury) tend to increase the likeli-
hood and severity of cognitive impairment in HIV-
infected individuals. On the contrary, patients with a
history of good virologic control and no history of
severe immunologic suppression have a reduced risk
of neurocognitive impairment. In terms of everyday
function, neurocognitive impairment is associated
with higher rates of unemployment, difficulty with
complex tasks such as driving, decreased ability to
adhere to antiretroviral treatment, and increased mor-
tality several years out from initial visit. Treatment
considerations such as starting antiretrovirals (ARVs)
early and including ARVs with high CSF penetration
to reduce CSF viral load (VL) and prevent or attenuate
HAND are promising, but still need further research.
Endeavors to establish HAND prevalence rates
across countries and regions of the world have yielded
varyingestimates, ranging from12%to56%.Empirical
questions regarding the nature of these different rates
(i.e., HIV clade differences, host responses and genet-
ics, differences in cofactors such as TB, malaria,
hepatitis, nutrition, etc.) are impeded by the lack of
comparable and reliable diagnostic methods used
across sites.
Treatment of HAND—penetration of antiretrovirals
into the CNS
As mentioned above, HAND is still a global problem.
Dr. Letendre’s talk focused on the possibility that the
limited distribution of drugs into the brain could be
contributing to this problem. Factors limiting drug
distribution into the CNS are based in the restrictive
nature of the blood-brain barrier (tight junctions and
astrocytic foot processes). As a result, diffusion of
drugs across the blood-brain barrier is determined in
part by characteristics such as protein binding, molec-
ular weight, lipophilicity, ionization, and molecular
pumps (e.g., P-glycoprotein and organic anion trans-
porters). Drugs within the different classes of antire-
trovirals differ in their CSF pharmacokinetics. For
example, the CSF concentration of the nucleo-
side reverse transcriptase inhibitor (NRTI) abacavir
reaches approximately 36% of plasma concentrations
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whereas tenofovir reaches approximately 5%. The PIs
darunavir and lopinavir differ in their CSF-to-plasma
ratios (1.4% versus 0.23%) as do NNRTIs such as
nevirapine and efavirenz (29–63% versus 0.5%).
These ratios, however, may not reflect efficacy in
the nervous system as well as metrics that estimate
the relationship between drug concentrations in the
nervous system and the concentrations that inhibit
HIV replication (e.g., the CSF-to-50% inhibitory con-
centration ratio). When antiretrovirals improve or
maintain cognition, they probably do so by reducing
HIV replication in the CNS and improving cellular
immunity. These effects are probably necessary for
improving or maintaining cognitive health but may
not always be sufficient because neurotoxins such as
HIV proteins, proinflammatory cytokines, oxidative
stress, and excitotoxins may persist even when HIV
levels are reduced below the quantitation limit of
commercial assays. In addition, immune recovery
may not result in recovery of neurotrophic or neuro-
protective molecules. The predominant cellular
source of HIV found in the nervous system may
determine the effectiveness of treatment on CNS
complications. When CD4+ cell counts are higher
and cognition is normal, HIV in the nervous system
may predominantly derive from migrating cells, such
as lymphocytes. In this situation, controlling HIV
in migrating cells is relatively more important and
penetration of antiretrovirals into the nervous system
may be relatively less important. However, when
CD4+ cell counts are lower or cognition is impaired,
HIV in the nervous system may derive predominan-
tly from resident cells, such as macrophages and
microglia. In this situation, controlling HIV may
require antiretrovirals that penetrate into the nervous
system in therapeutic concentrations. Additional
anti-inflammatory, antioxidant, or neuroprotective
therapies may also be warranted.
Dr. Letendre has devised a method of estimating
the penetration and effectiveness of antiretrovirals in
the nervous system. Ranks are assigned to each drug
and these ranks are summed to yield a value for a
given regimen, with higher scores indicating greater
penetration. In most analyses to date, higher pene-
tration ranks are associated with lower CSF viral
loads. Other analyses have also identified that esti-
mates of higher penetration are associated with better
neurocognitive performance, better mood, and better
survival.
HAND research and clinical care in Africa
Assessment of neurological complications in HIV-2
infection in West Africa
HIV-2 is uniquely prevalent in West Africa and
although the clinical course is more indolent than
HIV-1, pathological studies of brain tissue suggest
similar pathology to HIV-1 by time of death. Clinical
neurological manifestations of HIV-2, however, are
largely unstudied. Dr. Clifford, Dr. Jaye, and Dr. Diop
presented their aims for several cohorts underway to
develop the infrastructure for neurological evalua-
tion in West Africa in order to learn more about the
neurological complications of HIV-2. In addition to
development of infrastructure and sharing of exper-
tise, the aims of the cohorts include (1) studying the
prevalence and characteristics of neurocognitive
impairment, peripheral neuropathy, and myelopathy
in HIV-2-infected patients through the course of
disease; (2) collecting preliminary neuroimaging
and CSF samples from clinically characterized
HIV-2–affected patients; (3) investigating the associ-
ation of aging on HIV-2 neurological manifestations;
and (4) determining the spectrum of neurologic
opportunistic infections associated with HIV-2. The
two cohorts discussed are based in Caio, The Gambia,
and Dakar, Senegal.
NeuroAIDS in Cameroon
Dr. Kanmogne andDr. Njamnshi presented the prelim-
inary results of the Cameroon neuroAIDS project, a
case-control study aimed at investigating the epidemi-
ology of HIV-associated neurocognitive disorders in
Cameroon. From February 2008 to May 2009, the
Cameroon team enrolled 122 participants (85 HIV-
seropositive cases and 37 HIV-seronegative controls).
In this pilot study, both the Halstead Category Test
(HCT) andWisconsin Card Sorting Test-64 (WCST-64)
showedsignificant impairmentof theexecutive/frontal
lobe function inHIV-infected individuals, compared to
seronegative controls. Data further showed increased
impairment in HIV-seropositive individuals with
advanced immune deficiency.
As a baseline for a series of studies on HIV-
associated dementia (HAD), Dr. Njamnshi and collea-
gues assessed the usefulness of the recently developed
International HIV Dementia Scale (IHDS) as a
screening tool for HAD or HIV-associated cognitive
impairment in HIV-positive adults in Yaoundé,
Cameroon. In this case-control study, HIV-positive
adults followed up in an HIV outpatient clinic were
matched to HIV-negative subjects for age and sex and
screened using the IHDS. In particular, the IHDSmean
total score, alternating hand sequence, and 4-word
recallmeasureswere useful in distinguishing between
HIV patients at risk for dementia and normal healthy
subjects. The IHDS fingertapping subscore was not
significantly different between the two groups. Using
the IHDS screening tool, investigators estimated a
21.1% prevalence rate of HAND, and suggested that
future research on HAND in Cameroon should strate-
gically start with the IHDS as a screening tool.
Dr. Njamnshi and colleagues also investigated risk
factors for HAND such as low hemoglobin levels, low
bodymass index (BMI),more constitutional symptoms
before AIDS, age older than 68 at AIDS onset, intrave-
nous (IV) drug use, low CD4 counts, high plasma viral
loads, and antiretroviral (ARV) drug naivety. They
found that low CD4 count (<200/ml), advanced clinical
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stage (Centers of Disease Control and Prevention [CDC]
stage C), and low hemoglobin concentration (£10 g/dl)
independently predicted risk of HAND in Yaoundé,
Cameroon, and suggested that these factors could be
used to detect HIV-infected patients at risk of develop-
ing HAD, and included as criteria for eligibility to
highly active antiretroviral therapy (HAART).
Patterns of CNS involvement in the AIDS
population in Ethiopia
Utilizing postmortem forensic pathology cases in
AddisAbaba, Ethiopia, Dr. Langford andDr. Gemechu
are conducting autopsies to determine the frequency
of HIV infection and neuropathological patterns, as
well as the frequency of CNS involvement of
Mycobacterium tuberculosis in HIV+/ cases in this
region. Investigators hypothesized that approximately
15% of cases would be HIV+, 30% to 50% of these
cases would show evidence of CNS involvement, and
thatCNS involvement inTB+caseswouldbe greater in
HIV+ than in HIV cases. The design of this experi-
ment offered opportunities to characterize the natural
history of HIV in this population, observe HIV neuro-
pathogenesis at different stages of disease, and char-
acterize neuropathology patterns in HAART-naïve
patients. Half of the cases to be considered were
obtained from hospital settings and half from outside
settings. Additionally, half of the cases within each
group resulted fromnatural death, andhalf from injury
(accidental and intentional). Gross pathological obser-
vations of 188 cases at autopsy included 112 cases
(60%) suspected of chronic illness, 37 cases (20%)
suspected of CNS infection, and 84 cases (45%) with
suspected pulmonary TBwith pneumonia. Histopath-
ological analyses of the same 188 cases confirmed TB,
encephalitis, liver disease, or other CNS-related
pathologies in 42% of injury-related deaths. TB was
themost common histopathological finding from both
injury and natural cause groups, followed by liver
disease.TissuescollectedatMenelikHospital inAddis
Ababa included spleen, liver, lungs, lymphnodes, and
adrenal tissue from the periphery, and frontal cortex,
basal ganglia (lenticular nucleus), hippocampus, and
spinal cord from the nervous system. Investigators
noted the challenge of detecting HIV in tissue when
the density of the virus may be low. As a result, tissue
from the spleen and frontal cortexwere sent to Temple
University in Philadelphia for polymerase chain reac-
tion (PCR) analyses. Further analyses are pending.
Neuropsychological assessment in HIV/AIDS and
its challenges in a low-resource country (Zambia)
Dr. Wood and Dr. Banda spoke about their research
in Zambia, one of the poorest countries in Africa.
The HIV prevalence rate in Zambia is at 14% in a
population estimated at 12 million. Greater than 95%
of viral isolates obtained from Zambia are subtype C,
and the neurological manifestations and psycholog-
ical sequelae of subtype C–infected individuals in
this area are not yet known. These researchers and
their collaborators are taking measures to build the
necessary in-country capacity to conduct HIV-1 neu-
ropathogenesis research to determine the impact and
extent of HIV-associated neurological diseases in
Zambia. As part of these aims, they conducted a
pilot study among HIV adults and children from
around Lusaka to assess the utility of tools adapted
from Western/developed neuropsychological assess-
ments. Among adult controls, scores for the IHDS,
Color Trails 2, Timed Gait, and Grooved Pegboard
(dominant and non-dominant hand) fell below West-
ern norms, whereas scores for the Mini-Mental State
Examination and Color Trails 1 were comparable to
Western norms. These results reveal that setting/
culture and level/quality of education can influence
neuropsychological performance, but that Western
developed neuropsychological tests can be useful to
assess HIV+ individuals in Zambia, when tests are
adapted and performance compared to appropriate
controls from the same setting.
To determine the impact and extent of HIV-
associated neurological diseases in Zambia, re-
searchers are conducting a prospective, 12-month
longitudinal study, using a random sample of HIV
+ and HIV adults and children with no existing
neurological or medical problems. Analysis of per-
formance so far on the IHDS revealed that HIV+
overall performed more poorly than HIV, but no
differences between HIV+ treated and untreated indi-
viduals were indicated. Another interesting finding
was that HIV+ females tended to be more sensitive to
IHDS motor tasks. This ongoing study will continue
to analyze other adult and child assessments up to
12 months, and this preliminary data will then be
used to assess progression of neurological disease
over a longer period.
Dr. Grant also spoke briefly on a pilot study in
Zambia to test the feasibility of using the HIV Neu-
robehavioral Research Center (HNRC) International
neuropsychological test battery to assess HAND in
Zambia and lay the foundation for future neuroAIDS
projects. Due to the current lack of Zambian test
norms, US African American norms for this battery
were used, with constants added to all scaled and
T-scores in order to reduce demographic effects and
allow for impairment classification via a global def-
icit score. Using these methods, approximately 33%
of HIV+ subjects and 15% of HIV subjects had
neurocognitive impairment. Neuropsychologically
impaired HIV+ subjects reported more than twice
the number of cognitive complaints than those
considered normal, indicating that performance
relates to everyday life. The effects of HIV disease
were greatest on neuropsychological domains of
sensory-information processing, verbal fluency, and
executive functions. The results indicate that this NP
test battery shows sensitivity to HIV in Zambia where
clade C is common in addition to its sensitivity to
HIV in other international settings where clade B is
common. Use of African American norms, however,
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only partly removed demographic effects (and only
after adjustment), and Zambian norms for proper
demographic correction are clearly needed in the
future.
ACTG (AIDS Clinical Trials Group) 5199
International Neurological Study
Dr. Robertson and colleagues conducted the first
large-scale international neurological clinical trial
in resource-limited settings for HIV. The purpose
of this trial was to estimate the prevalence and
incidence of AIDS dementia and CNS opportunistic
infections, and study the changes in neurocognitive
functioning at the initiation of antiretroviral treat-
ment. Researchers conducted neurological and neu-
ropsychological examinations at sites in Brazil,
India, Malawi, Peru, South Africa, Thailand, and
Zimbabwe to examine the effects of three treatment
arms (3TC/ZDV/EFV, FTC/TDF/EFV, and FTC/ddI-
EC/ATV). The three sections of the neurological
examination consisted of a face-to-face interview,
an examination to observe the subject’s physical
and mental status, and a final summary section.
The neuropsychological examinations included the
Timed Gait Test, Finger-Tapping Test, Grooved
Pegboard Test, and the Verbal Fluency Test. These
neuropsychological examinations tested for fine
motor function, speed of processing, gross motor
function, motor control, balance, executive function,
speed, and attention, The neurological and neuro-
psychological examinations showed a relatively high
rate of peripheral neuropathy and other neurological
abnormalities, but a low prevalence of minor cog-
nitive motor disorder (MCMD) and AIDS dementia.
The unexpectedly low prevalence of cognitive
impairment may be a result of selection bias (higher
functioning patients enrolled), which future studies
should attempt to avoid. The results of the neuro-
psychological examinations showed the expected
variations between countries, which could be due
to differences in populations, cultures, HIV subtypes
or resistance patterns, or variations in test adminis-
tration. Overall performance on neuropsychological
examinations was similar between treatment arms.
Conclusions of the study indicate there were signif-
icant improvements in neuropsychological function
after initiation of antiretroviral therapy in resource-
limited settings, which could be contributed to the
control of HIV viral load through ARV effects and/or
practice effects. Dr. Robertson and colleagues are in
the final stages of developing a study to collect
normative comparison data at these sites to be uti-
lized by future neuropsychological studies.
Depression and HIV-associated neurocognitive
deficits: Botswana pilot studies
In the first of two pilot projects, Dr. Lawler proposed
to measure the incidence of depression and dementia
in Botswana, to observe the correlation between
depression and cognitive test performance, to learn
if performance on a screening test correlates with
other cognitive measures, and to determine whether
depression and/or cognitive impairment caused pro-
blems in daily activities. The tests used to measure
Dr. Lawler’s proposals were the International HIV
Dementia Scale (IHDS), Digit Symbol-Coding Test,
WHO-UCLA Verbal Learning Test, Beck Depression
Inventory–Fast Screen, Prime-MD Mood Module,
and Activities of Daily Living Scale (ADLs). In this
study of 120 randomly selected HIV+ individuals,
24% were depressed, 38% had dementia, and
approximately 10% suffered from both depression
and dementia. There was a strong correlation
between depression measures and incidence of
depression in Botswana was consistent with other
HIV studies in Africa. Furthermore, depression did
not affect cognitive task performance, and it was not
related to language, nationality of examiner, age,
education, or CD4 count. However, depressed indi-
viduals reported more difficulty with ADLs, in par-
ticular managing medications. Performance on the
screening test (IHDS) correlated with performance on
other cognitive measures. This study also reported
that dementia was not related to CD4 count or time
since HIV diagnosis, but was related to the length of
time on HAART.
The purpose of the second pilot study was to
develop culturally specific assessment tools, such
as the Botswana-specific Auditory Verbal Learning
Test, and to compare depression and cognitive per-
formance with well-matched groups of HIV+ and
HIV subjects. The tests used were Trails A, Digit
Symbol-Coding, Botswana Auditory Verbal Learning
Test, Action Fluency, Color Trails 2, Grooved Peg-
board, Prime-MD (Depression, Anxiety, Alcohol
Modules), and Activities of Daily Living Scale.
This project concluded that there was no significant
difference in depression between HIV+ and HIV
subjects (21% versus 17%), that HIV+ subjects
reported more suicidal ideation (15% versus 3%),
and that there was a significant difference in anxiety
between the two groups (42% versus 22%). Further-
more, HIV+ subjects were significantly impaired on
tests of processing speed, verbal learning and mem-
ory, fine motor speed, and executive functions. Also,
subjects reported that memory was the primary rea-
son they had difficulty adhering to medication
regimens.
Opportunities and challenges for NeuroAIDS
research in Nigeria
Dr. Adebamowo discussed the opportunities and
challenges of NeuroAIDS research in Nigeria.
Nigeria’s population of 150 million and adult HIV
prevalence of 2.89% afflict the nation with the sec-
ond largest population of HIV+ individuals in the
world. Additionally, Nigeria as a country has a low
percentage of GDP (gross domestic product) spent on
health care, a limited number of physicians and other
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care providers, and as a result only approximately
20% of adults have comprehensive correct knowl-
edge about AIDS. In efforts to take action against the
rising prevalence of HIV infection, the amount of
funding from the U.S. President’s Emergency Plan for
AIDS Relief (PEPFAR); preventing mother to child
transmission (PMTCT), increased significantly in the
past 4 years, from around $10 million to over $1.1
billion, which led to rapid improvement of HIV
counseling, screening, testing, support, and treat-
ment. PEPFAR funding has also significantly
improved the health care infrastructure throughout
the country. The HIV-Nigeria ACTION Program now
has 136 training centers, hub sites, ART sites, and
PMTCT sites throughout the country. PEPFAR is
the largest prospective cohort of HIV-infected indi-
viduals ever assembled, providing the statistical
power to evaluate rare events such as neurological
impairment. In addition, PEPFAR supports substan-
tial clinical, laboratory, and informatics infrastruc-
ture, allowing record linkage and access to biological
specimens. Colocation of research at PEPFAR sites
provides a cost effective strategy for study of
NeuroAIDS in Africa.
Studies of HIV-1–related neurocognitive
impairment in Nigeria
In Nigeria, the prevalence, clinical features, and
effects of treatment for HIV-related neurocognitive
impairment are unknown. Dr. Royal presented a
study in which treatment-naïve subjects in Nigeria
were evaluated for HIV-related neurocognitive
impairment. Assessments included clinical question-
naires, general clinical laboratory testing, CD4
counts, viral load, and viral strain studies as well
as previously validated cognition assessments such
as the Karnofsky Performance Scale, International
HIV Dementia Scale, and a detailed neurocognitive
battery. Screening was critical so that the researchers
could study the sole effects of HIV-induced neuro-
logical impairment rather than from other factors
such as head trauma, psychiatric illness, drug use,
learning disability, and active CNS infection. Con-
clusions drawn from this study were that these indi-
viduals had lower mean Karnofsky and IHDS scores
than HIV controls and that low IHDS scores corre-
lated with worse clinical status. In a small subset of
patients administered detailed neuropsychological
testing, low effect sizes were observed on the major-
ity of the tests. However, several tests were found to
be potentially quite sensitive for detecting neurocog-
nitive impairment in this group. Finally, analysis of
the specific HIV subtypes that are found in Nigeria
suggested a possible association for specific strains
with the presence of cognitive impairment. Approx-
imately 50% of patients in Nigeria are prescribed
AZT-anchored regimens, 30% TDF-containing regi-
mens, and approximately 20% receive regimens
containing d4T. This pilot study demonstrated
feasibility for performing future studies of HIV-
related neurocognitive impairment in Nigeria, which
includes the assessment of the effects of treatment of
the disorder.
HIV clades/subtypes
Subtype-associated differences in risk for dementia
in Uganda
Investigations into subtype-associated differences in
risk for HAND are currently underway throughout
the world, and Dr. Sacktor and Dr. Nakasujja pre-
sented some of their research on this topic in Uganda
where clades A and D are common. In a previous
retrospective study of 140 HIV seroconverters in
Rakai, Uganda, followed over 5 years, patients
with subtype D had a faster progression to AIDS
or death (Laeyendecker, 2006). Dr. Sacktor and
Nakasujja followed 60 antiretroviral-naïve HIV+
individuals at risk for HIV-associated cognitive
impairment in Uganda to determine if subtype D is
also associated with a greater risk of dementia com-
pared to subtype A. Individuals included in the
study completed the IHDS, Grooved Pegboard,
Timed Gait, WHO-UCLA Auditory Verbal Learning
Test, Symbol-Digit, Color Trails 1 and 2, and Digit
Span Forward and Backward. Using data from the
phylogenetic analysis of both gp41 and gag genes,
HIV+ individuals were classified as subtype A, C, D,
or A/D recombinants.
Results indicate that HIV subtype D is associated
with an increased risk of dementia compared to
subtype A. Of the HIV+ individuals with subtype D,
89% were categorized with dementia (MSK 1),
whereas only 24% of individuals with subtype A
received this rating. These results provide the first
evidence in well-characterized HIV+ patients at a
similar stage of HIV disease, suggesting that HIV sub-
types may have different biological properties with
respect to their capacity to cause HIV-associated
cognitive impairment.
Neuropsychological profile of patients commencing
HAART in Cape Town, South Africa—preliminary
findings
Subtype C is responsible for more than 90% of HIV-1
infections in South Africa and may differ from
subtype B in terms of protein binding sites, binding
characteristics, replicative capacity, and possibly in
neurotoxicity and risk for cognitive impairment. Dr.
Joska, Dr. Paul, and colleagues discussed a natural
mutation in the TAT protein in subtype C associated
with reduced monocyte chemokine regulation and
its relevance to the CNS. TAT is involved in the
migration of monocytes into the brain via up-regu-
lation of inflammatory cytokines and adhesion mole-
cules. TAT also disrupts the tight junctions in the
blood-brain barrier (BBB), therefore variations in the
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TAT protein could lead to variations in CNS
pathology.
An early report from Ethiopia suggested that HAD
is infrequent in clade C (Clifford et al, 2007), but
studies from India suggest that it is comparable to
clade B (Gupta et al, 2007). Dr. Joska, in collaboration
with the University of Missouri, conducted a pilot
study to determine if cognitive impairment exists in
clade C HIV in South Africa and to begin to define
neuroimaging biomarkers of CNS involvement. Cog-
nitive measures used included Hopkins Verbal
Learning Test–R, Brief Visual Memory Test–R, Stroop
Test, Color Trails, Digit Symbol, Grooved Pegboard,
Tapping, and Animal Fluency. Participants included
52 ART-naïve HIV patients (29.6 years of age;
9.7 years of education) and 25 controls (27.0 years
of age; 11.3 years of education). HIV patients per-
formed significantly worse on the measures of Digit
Symbol, Color Trails 2, Animal Fluency, and Stroop
Color-Word interference. Analysis of diffusion tensor
imaging (DTI) and fractional anisotropy also revealed
significant differences between these groups. These
preliminary results provide evidence for cognitive
impairment in HIV clade C infection in South Africa,
and these investigators plan to determine if cognitive
status is associated with a TAT defect and whether
or not relationships exist between cognitive status
and proviral DNA, inflammatory cytokines, and
neuroimaging.
Variation in neurocognitive impairment based on
HIV-1 subtype
A discussion of the effect of HIV-1 subtype on neu-
rocognitive impairment in pediatric infection was
presented by Dr. Boivin, Dr. Wong, and Mr. Bangir-
ana. These researchers sought to determine whether
HIV+ school-aged children in Uganda currently inel-
igible for ART demonstrate deficits relative to HIV
children and whether the risk for progressive
encephalopathy (PE) in children differs by subtype.
Subtype, along with other clinical indicators, may
be an important consideration for when to initiate
ART treatment and for antiretroviral selection (e.g.,
CNS penetration characteristics). One hundred and
two HIV-infected antiretroviral therapy (ART)-naïve
children (mean age = 8.8 years) and 104 noninfected
controls (mean = 8.9 years) completed the Kaufman
Assessment Battery for Children, 2nd edition
(KABC-2), Tests of Variables of Attention (TOVA)
auditory and visual tests, and the Bruininks/
Oseretsky Test for Motor Proficiency, 2nd edition
(BOT-2). HIV-1 subtype was defined by the compo-
sition of the env gene determined using a sequence-
specific real time PCR assay (Hoelscher et al, 2002).
Evaluation of performance demonstrated significant
differences between the HIV+ and HIV groups on
the KABC measures of memory, learning, and visual-
spatial tasks, visual TOVA response time, and
attention-deficit hyperactivity disorder (ADHD) score
and on the BOT’s manual dexterity, upper-limb
coordination, and speed and agility tests. There
were no differences between HIV+ and HIV chil-
dren on auditory TOVA. A comparison of HIV+
children with subtypes A and D indicated subtype
A children did more poorly than subtype D on
visual-spatial tasks and had more errors on visual
TOVA. No differences were reported between HIV+
children with subtype A versus subtype D on the
BOT and auditory TOVA.
In summary, ART-naïve HIV+ Ugandan school
age children have poorer neuropsychological per-
formance on working memory, visual-spatial pro-
cessing, ADHD index, and aspects of motor
development. HIV subtype A is associated with
poorer neuropsychological performance (visual spa-
tial processing and TOVA impulsivity), compared to
subtype D in treatment-naïve Ugandan children. HIV
subtypes A and D may be associated with different
risks for progressive encephalopathy (PE) in chil-
dren. HIV subtype influences on encephalopathy
may fundamentally differ between children and
adults as subtype D was associated with a greater
risk of dementia or HAND compared to subtype A in
Ugandan adults. The PE described here in children
may be less dependent on immune suppression but
instead may be influenced by HIV coreceptor use.
According to their pathogenic model of subtype
differences, subtype A, which is more CCR5-tropic,
may be more efficient than subtype D, which is
CXCR4-tropic at infecting CNS macrophage and
microglia cells. X4 virus may be more immunolog-
ically pathogenic because it infects a wider range of
cells in lymphoid tissue, but may replicate less
efficiently in the CNS.
Pediatric Neuroassessments in Africa
In 2007, an estimated 370,000 children became
newly infected with HIV. Over 90% of these
infections occurred in sub-Saharan Africa (WHO/
UNAIDS, 2008). More than 90% of new infections
in children occur vertically, during pregnancy, at
time of birth, or through breastfeeding (WHO/
UNAIDS, 2008). HIV infection in vertically infected
children impairs the development and growth of an
immature CNS, resulting in delayed acquisition of
neurodevelopmental milestones in the majority of
children in the pre-ART era (Diamond et al, 1987;
Epstein et al, 1986). Without treatment, approxi-
mately one half of children will die by 2 years of
age (Newell et al, 2004).
Neurocognitive assessments in HIV-infected chil-
dren, especially in Africa, are plagued by a long list
of confounding factors, which include the socioeco-
nomic status or quality of the home environment, the
emotional well-being of caregivers (i.e., depression),
and secondary effects of HIV such as malnutrition,
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quality of education, quality of prenatal care, and
treatment with antiretroviral drugs.
Neurobehavioral development in a pediatric
population exposed to HIV
HIV affects all domains of child functioning at least
to some extent. Motor development is the most
affected in term of severity, early onset, and persis-
tence across the age groups. Dr. Holding and collea-
gues investigated the role of weight-for-age and
disease stage in poor psychomotor outcome of
HIV-infected children in Kilifi, Kenya. They used a
locally developed and validated measure, the Kilifi
Developmental Inventory, to assess psychomotor
development in 48 children aged 6 to 35 months
prenatally exposed to HIV (exposed and infected
odds ratios [OR] versus exposed and not infected).
Investigators reported a significant main effect of HIV
status (F(2, 38.01) = 7.89, P < 001). Children in the
HIV-infected group had lower mean psychomotor
scores than both exposed but uninfected children
and controls. No significant differences were
observed between the HIV-exposed group and the
reference population. Disease stage had an inverse
relationship with psychomotor outcome. Mean psy-
chomotor scores by disease stage were stage 1, 0.40
(1.68); stage 2, 1.01 (1.93); stage 3, 1.46 (1.57).
Children in disease stages 2 and 3 differed signifi-
cantly from those of the reference population.
Weight-for-age had a positive relationship with psy-
chomotor outcome. These findings indicate that
weight-for-age and disease stage are viable, easily
measurable benchmarks to identify those children
at developmental risk. These findings also imply that
nutritional intervention and other measures aimed at
slowing down disease progression may delay the
onset and severity of psychomotor impairment in
the paediatric HIV population in Africa.
Effects of HIV and ARV exposure on child health
and neurodevelopment, Botswana
Perinatal ARV medications have led to dramatic
reductions in mother-to-child transmission (MTCT)
of HIV-1. One third of HIV+ pregnant women now
receive ARVs during pregnancy or labor, and HAART
useduringpregnancyisincreasing.Concernsrelatedto
possible negative effects of prenatal ARV exposure on
neurodevelopment have been raised, given the
unknown impact of ARVs on the developing brain
and issues of potential mitochondrial toxicity related
toNRTI exposure.A recent largewell-controlled study
showed no cognitive or motor differences between
ARV-exposed and -unexposed HIV children (Wil-
liams et al, 2010). HIV-exposed but uninfected chil-
dren have also shown poorer outcomes than HIV
unexposed children (Van Rie et al, 2008). Studies of
neurological and neurodevelopmental outcomes in
HIV/ARV-exposed but uninfected children have
yielded conflicting results and controlling for
confounding factors (access to care, substance abuse,
socioeconomic status [SES]) is problematic.
Dr. Kammerer, Dr. Lockman, and colleagues are
currently working on a project in Botswana to further
investigate the effects of ARV and HIV exposure in
children. Botswana has the second highest rate of
HIV in the world and infection affects all socioeco-
nomic levels. In addition, 33.7% of pregnant women
are HIV+, but significant government support has led
to >90% of pregnant women being tested for HIV and
>85% of HIV+ women taking ARVs. The primary
objectives of the current study are (1) to compare
neurodevelopmental outcomes following in utero
exposure to three-drug HAART (two or more NRTIs
and single NRTI [zidovudine]) among HIV-unin-
fected children born to HIV+ mothers (with similar
CD4 cell counts); (2) to prospectively compare neu-
rodevelopmental outcomes and rates of mortality;
and (3) to determine the biologic and social factors
most strongly associated with excess mortality and
neurodevelopmental delay between children who
are HIV exposed but uninfected and children
born to HIV-uninfected mothers in a setting with
HAART availability. Neurodevelopmental outcomes
will be measured by a combination of an adapted
US-normed test (Bayley Scales) that is used in com-
parable studies and tests developed and normed in
Africa (Abubakar et al, 2008). Maternal infection
status, mental health, physical health, social support,
and nutrition status will be assessed as well as form
of feeding (breastfeeding versus formula), health and
nutrition, vision, hearing, and neurological status.
Effects of HIV on the neurodevelopment of young
infants in Africa: experience from Malawi
Dr. Van Rie discussed her work on the effects of HIV
and ART on neurodevelopment of infants and chil-
dren in Africa. In Kinshasa, Democratic Republic of
Congo, Van Rie and colleagues concluded that the
vast majority of HIV-infected children, even young
children, present with severe motor and cognitive
developmental delay at time of diagnosis (Van Rie
et al, 2008). Access to HIV care accelerated motor
development, but did not result in a catch up of
cognitive development. Timing of care had no effect
on motor development but the cognitive develop-
ment of children who accessed care early (prior to
development of severe immunodeficiency) tended to
normalize within 1 year of care, whereas the cogni-
tive development remained delayed for those pre-
senting late (Van Rie et al, 2009). These findings
underscore the importance of early treatment of
HIV infection in children. Dr. Van Rie is currently
studying the effects of early ART (within the first 3 to
4 months of life) on neurodevelopment in Blantyre,
Malawi. Preliminary data indicate that children who
start treatment early may demonstrate neurodevelop-
mental delay (both motor and cognitive) at a very
early stage in life (age 3 months) but can achieve a
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motor and cognitive development similar to that of
HIV unexposed children by 6 months of age.
Overview of treatment issues
Implementing HIV treatment in Africa faces many
challenges such as a high disease burden, many
countries with poor health infrastructure, ensuring
quality of care with trained staff and appropriate
monitoring tests, getting people into care before
disease progression, dual epidemics of TB and
HIV, providing affordable and convenient regimens
with favorable toxicity profiles, and sustainability of
funding for ART programs. In spite of these chal-
lenges many countries are making progress in getting
ART to those in need. From the years 2004 to 2007,
South Africa, Uganda, Malawi, and Ghana, for exam-
ple, drastically increased the estimated number of
people receiving ART; however, only 27%, 33%,
35%, and 15% of the estimated number of people
needing ART were receiving medication based on
UNAIDS/WHO criteria.
Evolving changes of treatment implementation in
Africa
Dr. Ive reviewed the challenges and changes in HIV
treatment in Africa and discussed a 4-year program
called the NSP implemented in South Africa in 2007.
The NSP aims to (1) reduce the number of new HIV
infections by 50% and (2) reduce the impact of HIV
and AIDS on individuals, families, communities, and
society by expanding access to appropriate treat-
ment, care, and support to 80% of all people diag-
nosed with HIV. In particular, young people in the
age group 15–24 are a focus of all the interventions,
especially for behavior change–based prevention.
The interventions needed to reach the goals of the
NSP include (1) prevention; (2) treatment, care, and
support; (3) human and legal rights; and (4) moni-
toring, research, and surveillance. Training and sus-
taining valuable human resources (i.e., doctors and
nurses) is one of the biggest obstacles to providing
quality care. In areas where doctors are scarce, gov-
ernments and care providers may need to consider
“task shifting,” and delegate some activities to less
qualified personnel. Training of primary health care
nurses (rather than doctors) to initiate antiretroviral
treatment, lay counsellors (rather than nurses)
“pricking” patients for rapid HIV tests, and lay
counsellors (instead of social workers) for orphan
support activities, for example, may save time and
money. Another pitfall of treatment programs in
Africa is “stock outs” of antiretroviral drugs in gen-
eral or specific components of a drug regimen. Stock
outs are problematic because they undermine the
message of adherence, increase the chance of resis-
tance to first line regimens, and delay putting
patients onto therapy.
Two important changes in HIV clinics in Africa
involve the use of d4t and viral load monitoring.
From 2000 to 2004, d4t was a staple of ART in Africa
because it was effective and inexpensive. Long-term
use of the drug, however, was associated with a
significant number of adverse events (e.g., peripheral
neuropathy and lactic acidosis), which led to non-
adherence or necessitated a change in regimen. As a
result, d4t is now phasing out of treatment. Moni-
toring viral load on the other hand is becoming more
common. Although it was once believed to be too
expensive, the costs of late detection of treatment
failure and resulting high levels of drug resistance
now overshadow the costs of monitoring viral load.
HIV-associated CNS opportunistic infections and
immune reconstitution syndrome
Immune reconstitution inflammatory syndrome
(IRIS) is a paradoxical worsening of a patient’s clin-
ical condition that is attributable to the recovery of
the immune system after initiation of HAART. IRIS
occurs in 15% to 25% of patients on HAART and
in 20% to 45% of patients with OIs on HAART
(Shelburne et al, 2006). Approximately 50% of
patients that develop IRIS have been on HAART
for around 50 days but the syndrome can appear
earlier in treatment. Patients who are antiretroviral
naïve, have active or subclinical OIs at HAART
initiation, have CD4 count <50 cells/mm3, or have
a prompt decrease in viral load with HAART are at
greater risk for IRIS. Certain host genes can also make
a patient more susceptible. CNS infections associated
with IRIS include viral infections (JC virus: primary
multifocal leukoencephalopathy [PML]; varicella-
zoster virus [VZV]: vasculitis; cytomegalovirus
[CMV]: retinitis; Epstein-Barr virus [EBV], optic neu-
ropathy and primary CNS lymphoma), bacterial
infections (mycobacterial disease: TB, leprosy), fun-
gal infections (cryptococcal meningitis, candida
meningitis), and parasitic infections (toxoplasmosis).
Encephalitis directly attributable to HIV also occurs.
Dr. Nath presented three different cases showing
the spectrum of IRIS that clinicians encounter, as
well as a review of the histopathological correlates,
potential biomarkers, and treatment options for IRIS.
In the first case, a patient with cryptococcal menini-
gitis on HAART and treatment for cryptococcal infec-
tion for 8 months developed headache, photophobia,
and nausea while their CD4 count increased from 24
to 124 cells/mm3 and their viral load dropped to
undetectable levels. After treatment with dexameth-
asone 24 mg/day, the patient dramatically improved
and was diagnosed with IRIS with cryptococcal men-
ingitis(Venkataramanaetal,2006).Inthesecondcase,a
patientwithaCD4countof474andHIVviral load<200
developed an episode of aphasia and seizures after
10 years of HAART. In this case the dementia was
mediated by macrophages in the CNS. The patient
temporarily improved with steroids but then
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encountered more cognitive andmotor issues (Venka-
taramana et al, 2006). The last was a case of acute
encephalopathy with IRIS. A patient developed right
sideweakness and cognitive decline over a period of 8
weeks and then started HAART. Ten weeks later, the
CD4 count improved from 50 to 320 and the viral load
dropped from838,100 to4000, but thenover thecourse
ofanotherweekthepatientprogressivelydeclinedwith
focal and generalized seizures resulting in death with
complications this time attributed to CD8+ T cells
(Miller et al, 2004).
IRIS associated with progressive multifocal leu-
koencephalopathy (PML) is characterized by CD3
+ T cell and macrophage (CD68) infiltration, infection
of oligodendrocytes by JC virus, and inflammation
attributed mostly to perivascular CD8+ T lympho-
cytes, whereas CD4+ lymphocytes are absent. Neuro-
pathological findings include multiple demyelinating
foci in frontal, parietal, and temporal white matter
(mostly subcortical areas). Potential biomarkers for
IRIS include cytokines (e.g., interleukin-6 [IL-6]) and
markers of neuronal injury (axonal and synaptic pro-
teins). IRISusuallyonsetsafterseveralweeksofHAART
when the viral load drops and CD8+ T lymphocytes
spike, thenprogresses asCD4+T lymphocytes increase
and CD8 cells decline. Whenmanaging potential CNS-
associated IRIS, clinicians must first exclude effects of
drugs, nonadherence to drugs, and progression of
underlying disease. Then they must decide whether
to discontinue HAART and whether to give systemic
corticosteroids (Riedel et al, 2006). The treatment
options for IRIS are not ideal because steroids increase
risks from immune suppression and interruption of
HAART increases risk for resistance to therapy and
reemergence of IRIS upon resumption of HAART.
The current recommendations for use of steroids in
IRIS are high-dose steroids tapered with oral steroids
for a month (with OI prophylaxis) for catastrophic
IRIS, but the same treatment for symptomatic and
asymptomatic IRIS is debatable.
Discussion
Although research and treatment of HIV-associated
neurocognitive disorders has been going on for over
20 years in the developed world, much less has been
carried out in resource-limited setting (RLS) such as
Africa. Participants at the conference discussed
some of the gaps in the knowledge and care of
HAND in Africa and offered several ideas to work
towards bridging the gaps. One concern was that
HIV care providers in Africa may not have the same
general level of awareness of HAND or neuroAIDS
and a network to spread general information on the
disease may help. In addition to this need to spread
general information on HAND, forming working
consortiums and cooperative arrangements between
research groups were also of great interest.
Participants discussed establishing these arrange-
ments in order to share resources on tissue samples,
neuropsychological data and tools, and neuroimag-
ing amongst other needs and considered modeling
the consortium on the Institutional Development
Award (IDeA) program, which extends NIH
resources to foster health-related research in rural
and medically undeserved areas of the US. Possible
arrangements could include collaboration building
between medical schools and institutions in the
United States/Europe and RLS as well as site-to-
site (or south-to-south) sharing of expertise. If
research sites with adequate expertise can be iden-
tified, the field of HAND research in Africa could
benefit from networks developed on the continent,
which would have less overwhelming differences
between sites. Before these efforts can move forward,
however, a concrete set of training needs and
resources needs to be established.
Establishing a set of neurological screens, neuro-
psychological examinations, and functional assess-
ments that can be used across sites, however, is a
problem on its own. Even within Africa, differences
in culture, language, education, and access to
resources exist, which could affect performance,
interpretation, and validity of many instruments.
The issue of adapting, validating, and gathering
normative data for neuropsychological assessments
occupied much of the discussion section. Is it pos-
sible to develop and validate a set of tests that can be
used across cultures? Most participants agreed that
many instruments developed in Western setting can
be used in RLS, if properly adapted for education
level and culture of the setting; however, they also
established that developing one set of instruments to
be used across sites is not the best way to screen for
neurocognitive impairment. Instead, developing a set
of domains to be tested, in place of a strict set of tests,
may be useful. It may not be possible to test each
domain in every setting due to restraints on time,
staff, and multiple issues with language proficiency
and culture. Starting with a breadth of assessments
and working to develop a set of domains for each
setting might be better than creating many tests from
scratch or using the same tests across settings. To lay
the foundation for HIV neurological studies in RLS,
the ACTG 5199 International Neurological Study
selected a brief battery of neuropsychological tests
sensitive to HIV-associated changes and also geared
towards limiting cultural influences. In addition,
researchers at these sites will soon begin a normative
control study with a slightly expanded battery, aim-
ing to enroll approximately 2400 participants, in
order to address the lack of normative data in RLS.
The appropriateness of activities of daily living
scales and other functional assessment also came
into question. In RLS, where most people are unem-
ployed and don’t drive cars, and where work and
daily life are less complex, thus many existing instru-
ments may not be useful to determine functional
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impairment. The Bolton questionnaire developed in
Uganda represents an improvement in this area, but
developing other culturally appropriate functional
assessments, possibly with help from community
members, presents an ideal research project.
Other problems that occur with neuropsycholog-
ical instruments and neurological examinations
involve standardized administration, scoring, and
definitions of clinical outcomes. Cultural differences
in administration and interpretation of instructions
exist, so quality control to measure performance of
those giving assessments should be in place, and
methods for monitoring quality should be published
with research findings. Experimenter drift (away
from standardized assessment) is common in both
developed and developing settings, and must be
managed. Primary investigators should consider
observingmultiple testing sessions every fewmonths,
even if they don’t know the language. Reviewing CRFs
and rescoring neuropsychological tests randomly can
also help catch mistakes and reveal systematic errors.
Periodically reviewing training DVDs that model
appropriate testing techniques and blinding people
administering assessments as much as possible to
the disease status of the individual may also benefit
standardadministration.Regardingclinicaloutcomes,
depression, functional impairment, and cognitive
impairment are defined in different ways by different
studies, which create issues with comparing perfor-
mance and health across populations. The “Frascati
paper” in 2007 provided an update of the research
nosology for HAND and laid out a set of suggested
cognitive domains and definitions for cognitive and
functional impairment (Antinori et al, 2007). The key,
however, may not be a set of definitions, but rather for
researchers to be very specific when presenting find-
ings as to what definitions were used to define cogni-
tive/functional/behavioral impairment, and to point
out differences in those definitions from other studies.
There are many challenges to conducting neuro-
psychological assessments in pediatric populations
in Africa. Quality of home environment, physical
and mental well-being of caregivers, gestational
effects (MTCT and prenatal treatment), and malnu-
trition may all impact performance. Participants
discussed different strategies for evaluating neuro-
cognition in children, which included screening ver-
sus in-depth assessments, home- or village-based
evaluations when clinic access is difficult, use of
computers and cutting-edge developments, as well
as strategies for standardizing scores. One proposal
was to use reference groups of children based on age,
gender, and environment instead of large normative
data sets. Developing assessments appropriate to
cultural contexts that are sustainable (do not involve
published/copyrighted materials) and then deter-
mining appropriate developmental milestones for
assessments in resource-limited settings were also
discussed. Neuropsychological “interventions” to
boost positive neuroplasticity, such as games for
learning and development in school-age HIV+ chil-
dren, may compliment ART and help ameliorate
some of the neurocognitive effects of HIV.
In terms of neuropathogenesis, several areas were
considered. As older, better penetrating ARVs are
gradually replaced by newer drugs, some unintended
loss of neurocognitive benefits may occur. The
effects of HIV-2 dual infection on neurocognition,
aswell as the other opportunistic infections and cofac-
tors such as crystal methamphetamine abuse in South
Africa, were also of concern. Linking systemic immu-
nological activation and symptoms to CNS immune
activation and clarifying the clade- or subtype-related
mechanisms for disease need further attention. For
example, in adults, clade D demonstrates increased
neuropathogenesis over cladeA,whereas theopposite
effect was observed in children. Studies investigating
clade C have reported less motor effects than other
clades. These and other studies need to be replicated
to determine if clade-specific neurocognitive profiles
exist. Studies such as these are difficult to interpret,
however, because evenwithin clades, different motifs
and protein products exist. The differences in patho-
genesis may not be due to clades per se, but specific
proteinmotifswithin a genome that cause toxicity. Dr.
Nath demonstrated that even a single amino acid shift
can make a difference. If serine is substituted for cys-
teine, theTATprotein is less toxicbecause thecysteine
on TAT hooks in with cysteine on a receptor to open a
channel. Post-translational modifications of proteins
such as TATwithinmammalian cellsmake them1000
times more toxic than TAT produced from Esherichia
coli. Ultimately determining the mechanisms
behind clade-related differences in neurocognitive
impairment will be very complicated and require a
lot of sequencing data in addition to neurocognitive
assessments and analyses of other variables.
Conclusions
NeuroAIDS research in Africa faces many challenges,
but also offers many opportunities. Because sub-
Saharan Africa was the “ground zero” for the HIV
pandemic, the majority of HIV-infected individuals
reside there. If the effects of culture, language, and
education can be teased out, this large pool of pro-
spective patient populations presents opportunities to
investigate how differences in viral and host genetics
influence clinical presentation of neurocognitive dis-
ease. In addition, collections of postmortem tissue
samples acquired in the region could be valuable
resources for further characterizing the neuropatho-
genesis of HIV and comorbid conditions. The popu-
lation of the region is generally resource poor and at
high risk of disease, so access to treatment and
counseling provided by research is very meaningful.
Knowledge gained from HAND research in the region
could significantly improve HAND treatment
throughout the world.
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